Efficacy of a site-specific anti-Nectin-4 antibody-drug conjugate against Nectin-4-positive triple-negative breast cancer models
-N4MU01-PMMAE warrants further optimization to enhance its effectiveness against TNBC models. This study also re-enforces the rationale for the development of novel moderate affinity and highly stable targeted therapeutics against other cancers.
Authors
- Moralba Dominguez Garcia
- Maruti Uppalapati (ORCID: https://orcid.org/0000-0003-0101-2030)
- Fabrice Ngoh Njotu (ORCID: https://orcid.org/0000-0003-4731-5301)
- Jessica Pougoue Ketchemen (ORCID: https://orcid.org/0000-0002-4574-8720)
- Emmanuel Nwangele (ORCID: https://orcid.org/0000-0002-4269-822X)
- Humphrey Fonge (ORCID: https://orcid.org/0000-0001-9388-6872)
- Hanan Babeker (ORCID: https://orcid.org/0000-0001-9163-1323)
- Alireza Doroudi (ORCID: https://orcid.org/0000-0003-4021-0750)
- JOHN R. GORDON
- Eric W. Price
Institutions
- University of Saskatchewan (CA)
- Hôtel-Dieu de Québec (CA)
- Université Laval (CA)
Publication Details
- Journal
- International Journal of Pharmaceutics
- Published
- 2026-04-27
- DOI
- https://doi.org/10.1016/j.ijpharm.2026.126923
- Primary Topic
- Wnt/β-catenin signaling in development and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Canadian Cancer Society Research Institute
- Institute of Cancer Research